Heart Failure Trial Update- Analysis of Recent Data

Abstract The prevalence of heart failure (HF) continues to increase and its economic impact is significant in the US and globally. The past two years have seen a number of high quality clinical trials published, aiming to address different stages of the disease process and improve outcomes for both patients with preserved and depressed ejection fraction (EF). In this review, we summarize and critically appraise data from these trials. There are several important findings from these studies including but not limited to the benefit of dapagliflozin in HF with reduced EF, sacubitril-valsartan in acute decompensated heart failure, thoracotomy in LVAD implantation and the overall risk-benefit ratios of centrifugal pumps as opposed to continuous flow pumps. Effective therapies for HF with preserved EF continue to evolve for this varied group of high morbidity and mortality conditions.